{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:37:39Z","timestamp":1793147859885,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T00:00:00Z","timestamp":1763251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T00:00:00Z","timestamp":1763251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Egypt Heart J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ischaemic heart disease (IHD) is a leading cause of mortality and morbidity globally. Coronary angioplasty has a vital role in treating coronary artery disease. However, this is associated with a small risk of serious side effects, including contrast-induced nephropathy, vascular complications and arrhythmia. Contrast-induced nephropathy (CIN) is a serious and common complication of coronary angioplasty that can lead to renal failure and major adverse cardiac and renal outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review and meta-analysis by searching multiple databases, including PubMed, Scopus, Embase, Google Scholar, and ScienceDirect, as well as other sources. The inclusion and exclusion criteria are described in detail later in this article. Two independent reviewers performed the literature search in September 2024 and identified 282 articles. The study was conducted following the population, intervention, comparator, and outcome (PICO) framework and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A total of 17 studies were included in the final analysis after applying the inclusion and exclusion criteria. The exclusion criteria were guidelines, case reports, qualitative research, and letters to the editor, commentaries, conference proceedings, gray literature, opinions, policy papers, and case series. Articles published after 2010 were included in this meta-analysis, and data analysis was performed using Rayyan statistical software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study demonstrated that nicorandil was associated with protective effects against CIN. The total number of patients in the Nicorandil and placebo groups were 3836 and 3858 respectively. The occurrence of CIN was 5.14% in the nicorandil group, compared with 13.15% in the control group. This study also confirmed the dose-dependent effect of nicorandil on CIN. Among 662 patients enrolled in three studies, 3,9% in the double dose (DD) group presented with CIN, compared with 8,4% in the standard dose (SD) group. The occurrence of MACE was 5.7% in the Nicorandil group and 8.2% in the control group. However, there was no statistically significant protective effect against major adverse cardiovascular events (MACE) or major adverse kidney events (MAKE). Only a few studies measured the impact on MAKE, and the findings may not be truly representative of its effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study demonstrated the renoprotective effects of nicorandil in preventing CIN in patients undergoing coronary angioplasty, and this relationship was also evident from the double-dose response. Further larger size randomised controlled trials are recommended to assess the efficacy of nicorandil in preventing CIN in patients undergoing coronary angioplasty.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s43044-025-00705-4","type":"journal-article","created":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T16:38:39Z","timestamp":1763311119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Trials evaluating nicorandil renoprotection against contrast-induced nephropathy after coronary angiography or percutaneous coronary intervention: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"77","author":[{"given":"Nestor Lemos","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9bora Regina","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin G.","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Ashraf","family":"Shehab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abiodun Bamidele","family":"Adelowo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Rafi","family":"Damirchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Rathod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahid","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,16]]},"reference":[{"key":"705_CR1","doi-asserted-by":"publisher","unstructured":"Khan MAB, Hashim MJ, Mustafa H, Baniyas MY et al (2020) Shaikha Khalid Buti Mohamad Al Suwaidi, Rana AlKatheeri, Fatmah Mohamed Khalfan Alblooshi,. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study. Cureus 12 (7): e9349. https:\/\/doi.org\/10.7759\/cureus.9349","DOI":"10.7759\/cureus.9349"},{"key":"705_CR2","doi-asserted-by":"publisher","unstructured":"Sakboonyarat B (2024) and Ram Rangsin. Hospital Admission and Mortality Rates for Ischemic Heart Disease in Thailand: 2012\u20132021. BMC Research Notes 17 (1). https:\/\/doi.org\/10.1186\/s13104-024-06803-x","DOI":"10.1186\/s13104-024-06803-x"},{"issue":"02","key":"705_CR3","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1055\/s-0032-1333543","volume":"39","author":"M Franchini","year":"2013","unstructured":"Franchini M, Cervellin G, and Giuseppe Lippi (2013) Diagnosis and management of ischemic heart disease. Semin Thromb Hemost 39(02):202\u2013213. https:\/\/doi.org\/10.1055\/s-0032-1333543","journal-title":"Semin Thromb Hemost"},{"key":"705_CR4","doi-asserted-by":"publisher","unstructured":"Wu P, Yu S, Wang J, Zou S, Yao D-S, and Xin Yuan (2023) Global Burden, Trends, and inequalities of ischemic heart disease among young adults from 1990 to 2019: A Population-Based study. Front Cardiovasc Med 10. https:\/\/doi.org\/10.3389\/fcvm.2023.1274663","DOI":"10.3389\/fcvm.2023.1274663"},{"issue":"4","key":"705_CR5","doi-asserted-by":"publisher","first-page":"200125","DOI":"10.1148\/rg.2021200125","volume":"41","author":"S Sirajuddin, Arlene","year":"2021","unstructured":"Sirajuddin, Arlene S, Mojdeh Mirmomen SJ, Kligerman DW, Groves AP, Burke F, Kureshi CS, White, Arai AE (2021) Ischemic heart disease: noninvasive imaging techniques and findings. Radiographics 41(4):200125. https:\/\/doi.org\/10.1148\/rg.2021200125","journal-title":"Radiographics"},{"key":"705_CR6","unstructured":"Boucher J-F (2024) The Benefits of Early Diagnosis for Heart Disease. Laval Cardiovascular Evaluation Center. March 7, 2024. https:\/\/www.centrecardiolaval.com\/en\/2024\/03\/06\/the-benefits-of039early-diagnosis-for-heart-disease\/"},{"key":"705_CR7","unstructured":"John Hopkins Medicine. (2019) Coronary Artery Disease: Prevention, Treatment and Research. Johns Hopkins Medicine. 2019. https:\/\/www.hopkinsmedicine.org\/health\/conditions-and-diseases\/coronary-artery-disease-prevention-treatment-and-research"},{"key":"705_CR8","doi-asserted-by":"publisher","unstructured":"Gupta A, Neupane S, Basir M (2020) and Khaldoon Alaswad. Zero-Iodinated Contrast Retrograde Percutaneous Coronary Interventions of Chronic Total Occlusions Using Gadolinium and Imaging Guidance: A Case Report of a Patient with Severe Anaphylaxis to Iodinated Contrast. Edited by Parham Eshtehardi, Christoph Jensen, Romain Didier, Alice Wood, Carlos Minguito Carazo, and Peregrine Green. European Heart Journal - Case Reports 4 (3): 1\u20137. https:\/\/doi.org\/10.1093\/ehjcr\/ytaa092","DOI":"10.1093\/ehjcr\/ytaa092"},{"key":"705_CR9","doi-asserted-by":"publisher","unstructured":"Scherer K, Hammel J, Sellerer T, Mechlem K, Renger B, B\u00e4hr A, Kupatt C et al (2019) Dynamic quantitative iodine myocardial perfusion imaging with Dual-Layer CT using a Porcine model. Sci Rep 9(1). https:\/\/doi.org\/10.1038\/s41598-019-52458-1","DOI":"10.1038\/s41598-019-52458-1"},{"key":"705_CR10","doi-asserted-by":"publisher","unstructured":"Assen M, van M, Vonder GJ, Pelgrim PL, Von Doeberitz K, Vliegenthart R (2020) Computed tomography for myocardial characterization in ischemic heart disease: A State-of-The-Art review. Eur Radiol Experimental 4(1). https:\/\/doi.org\/10.1186\/s41747-020-00158-1","DOI":"10.1186\/s41747-020-00158-1"},{"key":"705_CR11","doi-asserted-by":"publisher","unstructured":"Ramsey BC, Fentanes E, Choi AD, Kelley R, Branch, and Dustin M. Thomas (2018) Myocardial assessment with cardiac CT: ischemic heart disease and beyond. Curr Cardiovasc Imaging Rep 11(7). https:\/\/doi.org\/10.1007\/s12410-018-9456-2","DOI":"10.1007\/s12410-018-9456-2"},{"issue":"1","key":"705_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/741018","volume":"2014","author":"M Andreucci","year":"2014","unstructured":"Andreucci M, Solomon R, and Adis Tasanarong (2014) Side effects of radiographic contrast media: Pathogenesis, risk Factors, and prevention. Biomed Res Int 2014(1):1\u201320. https:\/\/doi.org\/10.1155\/2014\/741018","journal-title":"Biomed Res Int"},{"key":"705_CR13","unstructured":"Stanek A (2025) Contrast Medium Reactions: Practice Essentials, Background, Pathophysiology. Medscape.com. Medscape. February 6, 2025. https:\/\/emedicine.medscape.com\/article\/422855-overview#a3"},{"issue":"3","key":"705_CR14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ccl.2019.04.004","volume":"37","author":"JE Novak","year":"2019","unstructured":"Novak JE, and Richa Handa (2019) Contrast nephropathy associated with percutaneous coronary angiography and intervention. Cardiol Clin 37(3):287\u2013296. https:\/\/doi.org\/10.1016\/j.ccl.2019.04.004","journal-title":"Cardiol Clin"},{"issue":"3","key":"705_CR15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.4103\/1995-705x.125926","volume":"14","author":"NMA Mohammed","year":"2013","unstructured":"Mohammed NMA, Rafie IM, Mahfouz A, Achkar K, and Rachel Hajar (2013) Contrast-Induced nephropathy. Heart Views 14(3):106. https:\/\/doi.org\/10.4103\/1995-705x.125926","journal-title":"Heart Views"},{"key":"705_CR16","unstructured":"Radiographic Contrast Agents - Special Subjects. n.d. MSD Manual Consumer Version. https:\/\/www.msdmanuals.com\/home\/special-subjects\/common-imaging-tests\/radiographic-contrast-agents"},{"issue":"1","key":"705_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S1878-6480(13)70958-3","volume":"5","author":"S Hamdi","year":"2014","unstructured":"Hamdi S, Elhraiech A, Chakroun M, Trimech T, Jomaa W, Selmi W, Hamda KB, Maatouk F (2014) 028: ascorbic acid prevents Contrast-Mediated nephropathy in patients undergoing coronary angiography. Archives Cardiovasc Dis Supplements 5(1):10. https:\/\/doi.org\/10.1016\/S1878-6480(13)70958-3","journal-title":"Archives Cardiovasc Dis Supplements"},{"issue":"15","key":"705_CR18","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.ehj.2004.04.037","volume":"25","author":"P NICOL","year":"2004","unstructured":"NICOL P (2004) Contrast agent nephropathy. Eur Heart J 25(15):1369. https:\/\/doi.org\/10.1016\/j.ehj.2004.04.037","journal-title":"Eur Heart J"},{"key":"705_CR19","doi-asserted-by":"publisher","unstructured":"Li Y, and Junda Wang (2024) Contrast-Induced acute kidney injury: A review of Definition, Pathogenesis, risk Factors, prevention and treatment. BMC Nephrol 25(1). https:\/\/doi.org\/10.1186\/s12882-024-03570-6","DOI":"10.1186\/s12882-024-03570-6"},{"issue":"February","key":"705_CR20","doi-asserted-by":"publisher","first-page":"e12975","DOI":"10.7717\/peerj.12975","volume":"10","author":"Z Mei","year":"2022","unstructured":"Mei Z, Luo S, Chen P, Zhang Q, Zhou L, Zhu C, Zhu H, and Lie Jin (2022) Efficacy of brain natriuretic peptide Vs. Nicorandil in preventing Contrast-Induced nephropathy: A network Meta-Analysis. PeerJ 10(February):e12975\u2013e12975. https:\/\/doi.org\/10.7717\/peerj.12975","journal-title":"PeerJ"},{"issue":"4","key":"705_CR21","doi-asserted-by":"publisher","first-page":"625","DOI":"10.2165\/00003495-199244040-00008","volume":"44","author":"J Frampton","year":"1992","unstructured":"Frampton J, Buckley MM, and Andrew Fitton (1992) Nicorandil Drugs 44(4):625\u2013655. https:\/\/doi.org\/10.2165\/00003495-199244040-00008","journal-title":"Nicorandil Drugs"},{"issue":"6","key":"705_CR22","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1159\/000503160","volume":"44","author":"Z Fan","year":"2019","unstructured":"Fan Z, Li Y, Ji H, and Xinwen Jian (2019) Efficacy of oral Nicorandil to prevent Contrast-Induced nephropathy in patients with chronic renal dysfunction undergoing an elective coronary procedure. Kidney Blood Press Res 44(6):1372\u20131382. https:\/\/doi.org\/10.1159\/000503160","journal-title":"Kidney Blood Press Res"},{"issue":"11","key":"705_CR23","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1007\/s00380-016-0809-y","volume":"31","author":"Y Fan","year":"2016","unstructured":"Fan Y, Wei Q, Cai J, Shi Y, Zhang Y, Yao L, Xiaogang Wang, et al (2016) Preventive effect of oral Nicorandil on Contrast-Induced nephropathy in patients with renal insufficiency undergoing elective cardiac catheterization. Heart Vessels 31(11):1776\u20131782. https:\/\/doi.org\/10.1007\/s00380-016-0809-y","journal-title":"Heart Vessels"},{"issue":"5","key":"705_CR24","doi-asserted-by":"publisher","first-page":"502","DOI":"10.5603\/cj.a2017.0028","volume":"24","author":"SF Leili Iranirad","year":"2017","unstructured":"Leili Iranirad SF, Hejazi MS, Sadeghi, Shahram Arsang J (2017) Efficacy of Nicorandil treatment for prevention of Contrast-Induced nephropathy in High-Risk patients undergoing cardiac catheterization: A prospective randomized controlled trial. Cardiol J 24(5):502\u2013507. https:\/\/doi.org\/10.5603\/cj.a2017.0028","journal-title":"Cardiol J"},{"issue":"4","key":"705_CR25","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3349\/ymj.2013.54.4.957","volume":"54","author":"Y-G Ko","year":"2013","unstructured":"Ko Y-G, Lee B-K, Kang WC, Moon J-Y, Cho YH, Choi SH, Myeong-Ki Hong, et al (2013) Preventive effect of pretreatment with intravenous Nicorandil on Contrast-Induced nephropathy in patients with renal dysfunction undergoing coronary angiography (PRINCIPLE Study). Yonsei Med Journal\/Yonsei Med J 54(4):957\u2013957. https:\/\/doi.org\/10.3349\/ymj.2013.54.4.957","journal-title":"Yonsei Med Journal\/Yonsei Med J"},{"issue":"8","key":"705_CR26","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/imj.13962","volume":"48","author":"S Li","year":"2018","unstructured":"Li S, Wang L, Liu Y, and Qiang Hu (2018) Preventive effect of Nicorandil on Contrast-Induced nephropathy: A Meta-Analysis of randomised controlled trials. Intern Med J 48(8):957\u2013963. https:\/\/doi.org\/10.1111\/imj.13962","journal-title":"Intern Med J"},{"issue":"2","key":"705_CR27","doi-asserted-by":"publisher","first-page":"e12316","DOI":"10.1111\/1755-5922.12316","volume":"36","author":"X Ma","year":"2018","unstructured":"Ma X, Li X, Zhanfeng Jiao, and, Zhang Y (2018) Nicorandil for the prevention of Contrast-Induced nephropathy: A Meta-Analysis of randomized controlled trials. Cardiovasc Ther 36(2):e12316. https:\/\/doi.org\/10.1111\/1755-5922.12316","journal-title":"Cardiovasc Ther"},{"issue":"9","key":"705_CR28","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1007\/s11255-023-03541-0","volume":"55","author":"A Abdollahi Moghaddam","year":"2023","unstructured":"Abdollahi Moghaddam A, Rahimi VB, Morovatdar N, Rezaee R, Sadegh Alavi B (2023) Oral Nicorandil effectively attenuates the incidence of Contrast-Induced nephropathy in patients undergoing cardiac catheterization: A Randomized, Controlled, Open-Label clinical trial. Int Urol Nephrol 55(9):2327\u20132334. https:\/\/doi.org\/10.1007\/s11255-023-03541-0","journal-title":"Int Urol Nephrol"},{"issue":"Autumn","key":"705_CR29","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ijcard.2015.05.078","volume":"195","author":"T Nawa","year":"2015","unstructured":"Nawa T, Nishigaki K, Kinomura Y, Tanaka T, Yamada Y, Kawasaki M, and Shinya Minatoguchi (2015) Continuous intravenous infusion of Nicorandil for 4 hours before and 24 hours after percutaneous coronary intervention protects against Contrast-Induced nephropathy in patients with poor renal function. Int J Cardiol 195(Autumn):228\u2013234. https:\/\/doi.org\/10.1016\/j.ijcard.2015.05.078","journal-title":"Int J Cardiol"},{"issue":"9","key":"705_CR30","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.carrev.2020.01.010","volume":"21","author":"R Pranata","year":"2020","unstructured":"Pranata R, Vania R, Alkatiri AA, Firman D, Antonia AL (2020) Nicorandil reduces the incidence of Contrast-Induced nephropathy in patients undergoing coronary Angiography\/Intervention \u2013 Systematic review and Meta-Analysis of randomized controlled trials including GRADE qualification. Cardiovasc Revascularization Med 21(9):1121\u20131127. https:\/\/doi.org\/10.1016\/j.carrev.2020.01.010","journal-title":"Cardiovasc Revascularization Med"},{"issue":"1","key":"705_CR31","doi-asserted-by":"publisher","first-page":"e000864","DOI":"10.1136\/openhrt-2018-000864","volume":"6","author":"AJ Sharp","year":"2019","unstructured":"Sharp AJ, Nishith Patel BC, Reeves GD, Angelini, and Francesca Fiorentino (2019) Pharmacological interventions for the prevention of Contrast-Induced acute kidney injury in High-Risk adult patients undergoing coronary angiography: A systematic review and Meta-Analysis of randomised controlled trials. Open Heart 6(1):e000864. https:\/\/doi.org\/10.1136\/openhrt-2018-000864","journal-title":"Open Heart"},{"key":"705_CR32","doi-asserted-by":"publisher","unstructured":"Wang X, Geng J, Zhu H, and Changying Xing (2018) Renoprotective effect of Nicorandil in patients undergoing percutaneous coronary intervention: A Meta-Analysis of 4 randomized controlled trials. Oncotarget 9(14). https:\/\/doi.org\/10.18632\/oncotarget.23965","DOI":"10.18632\/oncotarget.23965"},{"issue":"11","key":"705_CR33","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/s11255-019-02244-9","volume":"51","author":"Z Zeng","year":"2019","unstructured":"Zeng Z, Fu XF, Zhang X, and Naikuan Fu (2019) Comparison of Double-Dose vs. Usual dose of Nicorandil for the prevention of Contrast-Induced nephropathy after cardiac catheterization. Int Urol Nephrol 51(11):1999\u20132004. https:\/\/doi.org\/10.1007\/s11255-019-02244-9","journal-title":"Int Urol Nephrol"},{"issue":"3","key":"705_CR34","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/MCA.0000000000000927","volume":"32","author":"Z Zeng","year":"2021","unstructured":"Zeng Z, Zhang H, Zhang P, Li Y, Fu N (2021) Standard vs. Double dose of intravenous Nicorandil in preventing Contrast-Induced nephropathy in patients with coronary heart disease undergoing elective coronary procedures. Coron Artery Dis 32(3):256\u2013257. https:\/\/doi.org\/10.1097\/MCA.0000000000000927","journal-title":"Coron Artery Dis"},{"issue":"7","key":"705_CR35","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1177\/0003319717732237","volume":"69","author":"B Zhan","year":"2018","unstructured":"Zhan B, Huang X, Jiang L, Bao H, XiaoShu, Cheng (2018) Effect of Nicorandil administration on preventing Contrast-Induced nephropathy: A Meta-Analysis. Angiology 69(7):568\u2013573. https:\/\/doi.org\/10.1177\/0003319717732237","journal-title":"Angiology"},{"issue":"2","key":"705_CR36","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1177\/0003319719841733","volume":"71","author":"P Zhang","year":"2020","unstructured":"Zhang P, Li W-Y, Yang S-C, Fu N-K, Liu X-G, Zhang X, Cong H-L et al (2020) Preventive effects of Nicorandil against Contrast-Induced nephropathy in patients with moderate renal insufficiency undergoing percutaneous coronary intervention. Angiology 71(2):183\u2013188. https:\/\/doi.org\/10.1177\/0003319719841733","journal-title":"Angiology"},{"key":"705_CR37","doi-asserted-by":"publisher","unstructured":"Zhang X, Yang S, Zhang P, and Naikuan Fu (2019) Efficacy of Nicorandil on the prevention of Contrast-Induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention. Coron Artery Dis 1. https:\/\/doi.org\/10.1097\/mca.0000000000000826","DOI":"10.1097\/mca.0000000000000826"},{"key":"705_CR38","unstructured":"Role of Oral Nicorandil in Preventing (2018) Contrast induced nephropathy in type 2 diabetics undergoing coronary angiography | Cochrane Library. 2018. Cochranelibrary.com. https:\/\/www.cochranelibrary.com\/central\/doi\/10.1002\/central\/CN-01623567\/full"},{"issue":"Summer","key":"705_CR39","doi-asserted-by":"publisher","first-page":"1159741","DOI":"10.3389\/fphys.2023.1159741","volume":"14","author":"Y Ren","year":"2023","unstructured":"Ren Y, Chen L, Yuan Y, Xu J, Xia F, Zhu J, and Wen Shen (2023) Evaluation of renal cold Ischemia-Reperfusion injury with intravoxel incoherent motion Diffusion-Weighted imaging and blood oxygenation Level-Dependent MRI in a rat model. Front Physiol 14(Summer):1159741. https:\/\/doi.org\/10.3389\/fphys.2023.1159741","journal-title":"Front Physiol"},{"issue":"8","key":"705_CR40","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/ndt\/gfy149","volume":"33","author":"M Windpessl","year":"2018","unstructured":"Windpessl M, Kronbichler A (2018) Pro: contrast-Induced Nephropathy\u2014Should we try to avoid contrast media in patients with chronic kidney disease? Nephrol Dialysis Transplantation 33(8):1317\u20131319. https:\/\/doi.org\/10.1093\/ndt\/gfy149","journal-title":"Nephrol Dialysis Transplantation"},{"issue":"3","key":"705_CR41","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/s12325-016-0294-9","volume":"33","author":"U Pisano","year":"2016","unstructured":"Pisano U, Deosaran J, Leslie SJ, Rushworth GF, Stewart D, Ford I, and Angus (2016) Nicorandil, Gastrointestinal adverse drug reactions and ulcerations: A systematic review. Adv Therapy 33(3):320\u2013344. https:\/\/doi.org\/10.1007\/s12325-016-0294-9","journal-title":"Adv Therapy"},{"issue":"3","key":"705_CR42","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/cd9.0000000000000092","volume":"3","author":"P Li","year":"2023","unstructured":"Li P, Chen J, Li N, You X, Shen L, and Ning Zhou (2023) Real-World major adverse cardiovascular events of Nicorandil and nitrate in coronary heart disease in central china: A retrospective cohort study. Cardiol Discovery 3(3):152\u2013158. https:\/\/doi.org\/10.1097\/cd9.0000000000000092","journal-title":"Cardiol Discovery"}],"container-title":["The Egyptian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-025-00705-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43044-025-00705-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-025-00705-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:03:40Z","timestamp":1763424220000},"score":1,"resource":{"primary":{"URL":"https:\/\/tehj.springeropen.com\/articles\/10.1186\/s43044-025-00705-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,16]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["705"],"URL":"https:\/\/doi.org\/10.1186\/s43044-025-00705-4","relation":{},"ISSN":["2090-911X"],"issn-type":[{"value":"2090-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,16]]},"assertion":[{"value":"8 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}